RT Book, Section A1 Hayney, Mary S. A2 DiPiro, Joseph T. A2 Talbert, Robert L. A2 Yee, Gary C. A2 Matzke, Gary R. A2 Wells, Barbara G. A2 Posey, L. Michael SR Print(0) ID 1149032076 T1 Vaccines and Immunoglobulins T2 Pharmacotherapy: A Pathophysiologic Approach, 10e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259587481 LK accesspharmacy.mhmedical.com/content.aspx?aid=1149032076 RD 2024/03/29 AB Content UpdateNovember 20, 2017New Vaccine and Recommendations for Shingles: Shingrix is an inactivated recombinant vaccine licensed in the U.S. in October 2017. The vaccine has at least 90% efficacy in preventing shingles and is highly effective in preventing postherpetic neuralgia. It is recommended for healthy adults ages 50 years and older. Based on high efficacy rates, it is recommended over the previous live-attenuated vaccine Zostavax and is also recommended for adults who previously received Zostavax. Shingrix is given intramuscularly in two doses; the second dose is given 2 to 6 months after the first dose.